Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel Free CLBX Stock Alerts

Cellbxhealth (CLBX) Competitors

GBX 1.21 -0.04 (-3.12%)
As of 11:50 AM Eastern
Compare

CLBX vs. REDX, ETX, HVO, HEMO, and COIL

Should you buy Cellbxhealth stock or one of its competitors? Cellbxhealth's main competitors and comparable companies include Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), and Roquefort Therapeutics (COIL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellbxhealth compare to Redx Pharma?

Cellbxhealth (LON:CLBX) and Redx Pharma (LON:REDX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Redx Pharma'saverage media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Redx Pharma Neutral

0.4% of Cellbxhealth shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 1.2% of Cellbxhealth shares are owned by insiders. Comparatively, 18.4% of Redx Pharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Cellbxhealth has higher earnings, but lower revenue than Redx Pharma. Cellbxhealth is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M11.95N/A-£3.49N/A
Redx Pharma£4.20M0.00-£33.16M-£0.10N/A

Cellbxhealth's return on equity of 0.00% beat Redx Pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Redx Pharma N/A -180.80%-43.95%

Summary

Redx Pharma beats Cellbxhealth on 4 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to e-therapeutics?

Cellbxhealth (LON:CLBX) and e-therapeutics (LON:ETX) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.

Cellbxhealth's return on equity of 0.00% beat e-therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
e-therapeutics N/A -38.75%-29.10%

In the previous week, e-therapeutics had 1 more articles in the media than Cellbxhealth. MarketBeat recorded 1 mentions for e-therapeutics and 0 mentions for Cellbxhealth. Cellbxhealth's average media sentiment score of 0.00 beat e-therapeutics' score of -0.15 indicating that Cellbxhealth is being referred to more favorably in the media.

Company Overall Sentiment
Cellbxhealth Neutral
e-therapeutics Neutral

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Cellbxhealth has higher revenue and earnings than e-therapeutics. Cellbxhealth is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M11.95N/A-£3.49N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

Summary

Cellbxhealth beats e-therapeutics on 5 of the 9 factors compared between the two stocks.

How does Cellbxhealth compare to hVIVO?

hVIVO (LON:HVO) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

hVIVO has higher revenue and earnings than Cellbxhealth. hVIVO is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M0.95£17.84M-£0.87N/A
Cellbxhealth£1.15M11.95N/A-£3.49N/A

hVIVO currently has a consensus target price of GBX 15, indicating a potential upside of 133.46%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts plainly believe hVIVO is more favorable than Cellbxhealth.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Cellbxhealth
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

In the previous week, hVIVO's average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
hVIVO Neutral
Cellbxhealth Neutral

Cellbxhealth has a net margin of 0.00% compared to hVIVO's net margin of -12.48%. Cellbxhealth's return on equity of 0.00% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Cellbxhealth N/A N/A N/A

12.7% of hVIVO shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

hVIVO beats Cellbxhealth on 8 of the 12 factors compared between the two stocks.

How does Cellbxhealth compare to Hemogenyx Pharmaceuticals?

Cellbxhealth (LON:CLBX) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Cellbxhealth has higher revenue and earnings than Hemogenyx Pharmaceuticals. Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellbxhealth£1.15M11.95N/A-£3.49N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

0.4% of Cellbxhealth shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 1.2% of Cellbxhealth shares are held by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Cellbxhealth's average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Cellbxhealth Neutral
Hemogenyx Pharmaceuticals Neutral

Cellbxhealth's return on equity of 0.00% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
CellbxhealthN/A N/A N/A
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

Summary

Cellbxhealth beats Hemogenyx Pharmaceuticals on 6 of the 7 factors compared between the two stocks.

How does Cellbxhealth compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Cellbxhealth (LON:CLBX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Cellbxhealth has higher revenue and earnings than Roquefort Therapeutics. Roquefort Therapeutics is trading at a lower price-to-earnings ratio than Cellbxhealth, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Cellbxhealth£1.15M11.95N/A-£3.49N/A

Cellbxhealth has a net margin of 0.00% compared to Roquefort Therapeutics' net margin of -57,057.07%. Cellbxhealth's return on equity of 0.00% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Cellbxhealth N/A N/A N/A

1.9% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 0.4% of Cellbxhealth shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by company insiders. Comparatively, 1.2% of Cellbxhealth shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Cellbxhealth'saverage media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Cellbxhealth Neutral

Summary

Cellbxhealth beats Roquefort Therapeutics on 6 of the 8 factors compared between the two stocks.

Get Cellbxhealth News Delivered to You Automatically

Sign up to receive the latest news and ratings for CLBX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CLBX vs. The Competition

Export
MetricCellbxhealthBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£13.76M£4.03B£7.31B£2.92B
Dividend YieldN/A3.64%2.54%6.17%
P/E Ratio-0.3511.87271.23367.27
Price / Sales11.951,430.15696.7783,460.67
Price / CashN/A44.9429.0327.89
Price / BookN/A17.4911.337.12
Net IncomeN/A-£22.72M£3.46B£5.89B
7 Day Performance-9.56%4.71%3.26%0.74%
1 Month Performance-8.60%12.24%8.85%3.13%
1 Year PerformanceN/A60.75%27.68%22.34%

Cellbxhealth Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CLBX
Cellbxhealth
N/AGBX 1.21
-3.1%		N/AN/A£13.76M£1.15MN/AN/A
REDX
Redx Pharma
N/AN/AN/AN/A£58.35M£4.20MN/A101
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
HVO
hVIVO
N/AGBX 6.69
+2.1%		GBX 15
+124.3%		-34.6%£46.03M£46.77MN/AN/A
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 608
+1.9%		N/A+233.0%£41.34MN/AN/A14

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:CLBX) was last updated on 8/25/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel